External broker reports(aggregated public sources), Sharekhan

Sharekhan

Sharekhan is India's leading broking house providing services from easy online trading, research to wide array of financial products. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Sharekhan's research report onLupin The US is witnessing benign price erosion pressure followed by healthy uptick in respiratory portfolio led by gSpiriva witnessing a 30-35% conversion rate.</li><li>This to result in $200-220 million sales on a quarterly basis.</li><li>USFDA recently completed cGMP inspection of Dabhasa plant and zconcluded with no observations.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sharekhan's research report onLupin The US is witnessing benign price erosion pressure followed by healthy uptick in respiratory portfolio led by gSpiriva witnessing a 30-35% conversion rate.This to result in $200-220 million sales on a quarterly basis.USFDA recently completed cGMP inspection of Dabhasa plant and zconcluded with no observations.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lupin Ltd - GSpiriva on a Healthy Growth Track, Headwinds Receding